Parmir Therapeutics, Inc. is a biotechnology company
dedicated to developing in vitro diagnostic (IVD) kits
and therapeutics based on extensive research
expertise in Parkinson’s disease and Alzheimer’s disease.

As a complementary approach to high-cost imaging systems such as PET-CT,
we are developing affordable RT-qPCR-based IVD kits that use blood-based
microRNA biomarkers associated with Parkinson’s disease or Alzheimer’s disease.

Through this technology, we aim to enable rapid early diagnosis and expand access to medical screening worldwide.

Furthermore, we aim to go beyond symptom relief by developing disease-modifying therapies that regulate disease-related gene expression and inhibit protein aggregation in Parkinson’s disease. Through these efforts, We strive to improve therapeutic outcomes and enhance the quality of life for patients.

Rooted in a deep respect for life, everyone at Parmir Therapeutics, Inc. is committed to continuous research and innovation. We strive to develop innovative solutions that bring meaningful hope to patients with Parkinson’s disease or Alzheimer’s disease and their families.

Chief Executive Officer

Cheolkee Moon